

レジメン名

Tremelimumab+Durvalumab

出典 イミフィンジ・イジユド適正使用ガイド
2023年3月作成
HIMALAYA試験

実施部署区分

■入院 ■外来 □処置

対象疾患

肝細胞癌
■進行・再発
□補助療法(術前・術後)
□
□

1クール期間 28日

総クール数 PD

(次のクールまでの標準期間)

Table with 3 columns: Organ/System, Grade, and Action. Rows include Interstitial lung disease, Myocarditis, Thyroid dysfunction, Skin toxicity, Infusion reaction, GI perforation, and Other side effects.

投与中止・減量の基準

Table with 4 columns: Organ/System, Lab Value, Threshold, and Action. Rows include Liver function, CR, Myocarditis, and Neurotoxicity.

Table with 5 columns: Drug Name/Abbreviation, Daily Dose, Administration Method, Administration Speed, and Administration Day. Rows for Tremelimumab and Durvalumab.

Table with 1 column: Administration Order (1日投与順). Details on timing and use of inline filters for 1 and 2 course administrations.